BRCA2 and ovarian carcinoma: Consistent with the previously published results55, we also observed that BRCA2-mutated ovarian cancer cells PEO1 showed reduced sensitivity to the PARPi olaparib (Fig. 8b and Supplementary Fig. 11b).